ArticleBMJ global health2026
Data reuse in global health: perspectives from actors in policy, funding and research.
Article in BMJ global health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundData-sharing mandates from funders and journals have increased in recent years, but little is known about how shared data are used. Existing research has focused on access frameworks, with less attention to conditions that enable or hinder subsequent analyses and their impact on science and policy.
methodsWe conducted semi-structured interviews with 22 key informants with experience using clinical research data. Participants included researchers, policy makers and senior staff from funding and pharmaceutical organisations. Interviews explored motivations, ethical and practical challenges, and enabling conditions for reuse. Data were analysed thematically using a combination of deductive and inductive coding. Reporting follows the Consolidated criteria for Reporting Qualitative research framework.
resultsSecondary data analyses have, in a few documented cases, shaped clinical guidelines and policy in low- and middle-income countries (LMICs). Individual participant data meta-analyses informed WHO recommendations for maternal and child health interventions, and analyses of COVID-19 data guided decisions at national and subnational levels in several countries. However, such cases remain uncommon. Secondary data users reported that shared data were seldom ready for analysis owing to incomplete metadata and under-resourced data curation. In academia, secondary analyses were driven by the potential for publication rather than health impact. Mistrust, particularly where data contributors feared reputational harm or exploitation, resulted in underutilisation of valuable data as analysts relied on a limited set of well-known or easily accessible datasets. This risks selection bias and limits the evidence base, especially for under-represented groups.
conclusionsMandating data sharing alone is insufficient to deliver impact in LMICs. Policies must be coupled with resourcing for data curation, efforts to avail machine-actionable metadata and incentives for impact-driven analyses. Equally critical is trust, built through recognition of contributors and equitable, transparent benefit-sharing between analysts and data generators.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.